恩度联合肝动脉化疗栓塞治疗中晚期肝癌28例

Endostar plus transcatheter arterial chemoembolization for advanced hepatocellular carcinoma

目的:探讨恩度联合肝动脉化疗栓塞治疗中晚期肝癌的疗效、不良反应。方法:60例中晚期原发性肝癌患者分为两组。实验组28例,予恩度联合肝动脉化疗栓塞治疗;对照组32例,予常规肝动脉化疗栓塞治疗。对治疗前后实体肿瘤疗效、血清血管内皮生长因子(VEGF)、甲胎蛋白(AFP)的变化及不良反应等进行分析。结果:两组不良反应均较轻微,实验组治疗后实体肿瘤缓解率和AFP转阴率较对照组显著提高(P<0.05);两组患者血清VEGF表达水平在术后3d均显著升高,实验组术后7d血清VEGF表达水平能迅速下降,与对照组比较差异有统计学意义(t=5.43,P<0.05)。结论:恩度联合肝动脉化疗栓塞治疗中晚期原发性肝癌的肿瘤的近期疗效显著,副作用小,安全性好,是一种值得临床应用的治疗方法。

Objective To investigate the therapeutic effects and adverse effects of endostar plus transcatbeter arterial ehemoembolization （TACE） on advanced hepatocellular carcinoma （HCC）. Methods 60 patients with HCC were assigned to receive endostar plus TACE （experiment group, n = 28） or TACE alone （control group, n = 32）. The therapeutic effects and adverse effects, serum levels of vascular endothelial growth factor （VEGF） and alpha-fetoprotein （AFP） were analyzed. Results No obvious adverse effects were observed in the two groups. The overall response rate and negative conversion rate of AFP in experiment group after treatment were significantly increased as compared to those in control group （P 〈 0.05）. Serum levels of VEGF in the two groups were significantly elevated at day 3 after operation, and was decreased rapidly at day 7 in experiment group （vs control group, F = 3.64, P 〈 0.05）. Conclusion Endostar plus TACE can effectively treat advanced HCC with few adverse effects, which is worth applying in clinic.